Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Xeris Biopharma Holdings Inc shares valued at $173,402 were sold by Shannon John Patrick Jr on Nov 13 ’25. At $7.46 per share, Shannon John Patrick Jr sold 23,242 shares. The insider’s holdings dropped to 2,643,153 shares worth approximately $18.74 million following the completion of this transaction.
Also, Hecht Beth sold 16,667 shares, netting a total of over 123,296 in proceeds. Following the sale of shares at $7.40 each, the insider now holds 1,336,843 shares.
Before that, JOHN SHANNON had added 48,149 shares to its account. In a trade valued at $365,451, the Director bought Xeris Biopharma Holdings Inc shares for $7.59 each.
Analysts at Piper Sandler downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid November. As of March 28, 2024, Oppenheimer has initiated its “an Outperform” rating for XERS. Earlier on August 28, 2023, Craig Hallum initiated its rating. Their recommendation was “a Buy” for XERS stock.
Analyzing XERS Stock Performance
On last trading session, Xeris Biopharma Holdings Inc [NASDAQ: XERS] rose 0.14% to $7.09. The stock’s lowest price that day was $7.02, but it reached a high of $7.25 in the same session. During the last five days, there has been a drop of approximately -6.59%. Over the course of the year, Xeris Biopharma Holdings Inc shares have jumped approximately 142.81%. Shares of the company reached a 52-week high of $10.08 on 11/05/25 and a 52-week low of $3.14 on 01/13/25.
Support And Resistance Levels for Xeris Biopharma Holdings Inc (XERS)
According to the 24-hour chart, there is a support level at 6.99, which, if violated, would cause prices to drop to 6.89. In the upper region, resistance lies at 7.22. The next price resistance is at 7.35. RSI (Relative Strength Index) is 32.45 on the 14-day chart, showing neutral technical sentiment.
Is Xeris Biopharma Holdings Inc subject to short interest?
Stocks of Xeris Biopharma Holdings Inc saw a sharp rise in short interest on 2025-10-31 jumping by 0.19 million shares to 17.63 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 17.44 million shares. A jump of 1.05% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.01 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.01.
Which companies own the most shares of Xeris Biopharma Holdings Inc (XERS)?
In terms of Xeris Biopharma Holdings Inc share price expectations, FactSet research, analysts set an average price target of 18 in the next 12 months, up nearly 154.24% from the previous closing price of $7.08. Analysts anticipate Xeris Biopharma Holdings Inc stock to reach 18 by 2025, with the lowest price target being 18. In spite of this, 3 analysts ranked Xeris Biopharma Holdings Inc stock as Buy at the end of 2025. On October 21, 2022, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $4.
